PROCEPT BioRobotics (NASDAQ:PRCT) Releases Quarterly Earnings Results, Misses Estimates By $0.07 EPS

PROCEPT BioRobotics (NASDAQ:PRCT) announced its earnings results on Wednesday. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.07), FiscalAI reports. PROCEPT BioRobotics had a negative net margin of 32.60% and a negative return on equity of 32.71%. The company had revenue of $98.29 million during the quarter, compared to analysts’ expectations of $100.52 million. During the same period in the prior year, the business earned ($0.38) earnings per share. The company’s revenue for the quarter was up 18.0% compared to the same quarter last year.

Here are the key takeaways from PROCEPT BioRobotics’ conference call:

• PROCEPT reported third-quarter revenue of $98.3 million, up 18% year over year, with U.S. procedures rising 22% and U.S. handpiece and consumable revenue increasing 21%. Handpiece pricing remained strong, and the company said field inventory had normalized.
• Procedure growth remains challenged by weaker utilization on legacy AquaBeam systems as surgeons shift cases to HYDROS; HYDROS accounts performed more than 35% more procedures than legacy accounts. Management expects about 54,000 procedures for 2026, within its guidance range, but reaching that level implies the strongest sequential procedure growth of the year in Q4.
• The company placed 62 HYDROS systems, including 20 replacements, at an average U.S. selling price of about $495,000. Although greenfield placements fell short of expectations in Q3 due largely to timing, management maintained that it expects to meet or exceed its initial full-year system targets and said capital demand remains healthy.
• The net loss widened to $26.5 million from $21.4 million a year earlier, and adjusted EBITDA loss increased to $9.8 million from $7.4 million as operating expenses rose with investment. Management expects positive adjusted EBITDA in Q4 and described approximately 20% revenue growth in 2027 as a planning baseline, while noting that formal guidance will come later.

PROCEPT BioRobotics Stock Up 0.2%

NASDAQ:PRCT traded up $0.04 on Friday, reaching $20.31. 536,412 shares of the stock traded hands, compared to its average volume of 1,505,098. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -10.08 and a beta of 0.88. The company has a current ratio of 6.55, a quick ratio of 5.35 and a debt-to-equity ratio of 0.15. PROCEPT BioRobotics has a 12 month low of $16.67 and a 12 month high of $38.11. The company’s fifty day simple moving average is $19.32 and its 200 day simple moving average is $23.18.

Analyst Ratings Changes

A number of brokerages have commented on PRCT. Barclays began coverage on PROCEPT BioRobotics in a research note on Tuesday, October 6th. They issued an “overweight” rating and a $30.00 price target on the stock. Leerink Partners increased their price objective on PROCEPT BioRobotics from $20.00 to $22.00 and gave the company a “market perform” rating in a research note on Thursday. Robert W. Baird set a $20.00 target price on shares of PROCEPT BioRobotics in a report on Wednesday, August 5th. TD Cowen cut their target price on shares of PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating on the stock in a report on Wednesday, August 5th. Finally, William Blair lowered shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Three research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $25.00.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation is a medical technology company focused on developing and commercializing robotic solutions for the treatment of benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate that can cause urinary symptoms. The company’s technology is designed to provide a minimally invasive alternative to conventional surgical procedures.

Its primary product is the AquaBeam Robotic System, which uses image guidance, robotic assistance and a high-velocity waterjet to remove targeted prostate tissue.